1. Report Overview

1.1 Global Next-Generation Antibody Therapies Market Overview

1.2 Global Next-Generation Antibody Therapies Market Segmentation

1.3 Why you Should Read this Report?

1.4 How this Report Delivers

1.5 Main Questions Answered by This Analytical Study

1.6 Who is This Report For?

1.7 Methodology

1.8 Frequently Asked Questions (FAQ)

1.9 Associated Reports

1.10 About Visiongain

2. Introduction to Next-Generation Antibody Therapies

2.1 Market Definition & Scope of this Report

2.2 Antibodies: An Overview

2.2.1 Monoclonal vs Polyclonal Antibodies

2.2.2 A Brief History of Antibody Drug Development

2.2.3 The Antibody Manufacturing Process

2.2.4 Trends in Antibody Development

2.3 Defining Next-Generation Antibodies

2.4 Classification of Next-Generation Antibody Therapies

2.5 The Need for Next-Generation Technologies

2.6 Development Trends for Next-Generation Antibodies

2.7 Phases of Clinical Trials



3. Global Next-Generation Antibody Therapies Market, 2017-2028

3.1 The Global Next-Generation Antibody Therapies Market Overview and Segmentation, 2017

3.2 Leading Next-Generation Antibody Therapies

3.3 Global Next-Generation Antibody Therapies Market: Sales Forecast 2017-2028

3.4 How Will Segments Market Shares Change to 2028?

3.5 Global Next-Generation Antibody Therapies Market: Drivers and Restraints 2017-2028

3.6 Global Next-Generation Antibody Therapies Market by Product Type, 2017-2028

4. Global Next-Generation Antibody Therapies Market by Product Type: Revenue Forecast, 2018-2028

4.1 Antibody-Drug Conjugates Submarket

4.1.1 Global Antibody-Drug Conjugates Submarket: Revenue Forecast, 2018-2028

4.2 Engineered Antibodies Submarket

4.2.1 Global Engineered Antibodies Submarket: Revenue Forecast, 2018-2028

4.3 Bispecific Antibodies Submarket

4.3.1 Global Bispecific Antibodies Submarket: Revenue Forecast, 2018-2028

4.4 Antibody Fragments and ALPs

4.4.1 Global Antibody Fragments and ALPs Revenue Submarket: Forecast, 2018-2028

4.5 Biosimilar Antibody Submarket

4.5.1 Global Biosimilar Antibody Submarket: Revenue Forecast, 2018-2028

4.6 Segment Share Analysis by Product Type

5. Global Next-Generation Antibody Therapies Market by Regional and National Market: Revenue Forecast, 2018-2028

5.1 Global Next-Generation Antibody Therapies Market by Region: Revenue Forecast, 2018-2028

5.2 North America

5.2.1 North America Next-Generation Antibody Therapies Market by Country: Revenue Forecast, 2018-2028

5.2.2 US Next-Generation Antibody Therapies Market: Revenue Forecast, 2018-2028

5.2.3 Canada Next-Generation Antibody Therapies Market: Revenue Forecast, 2018-2028

5.2.4 Mexico Next-Generation Antibody Therapies Market, Revenue Forecast, 2018-2028

5.3 Europe

5.3.1 Europe Next-Generation Antibody Therapies Market by Country: Revenue Forecast, 2018-2028

5.3.2 Germany Next-Generation Antibody Therapies Market: Revenue Forecast, 2018-2028

5.3.3 France Next-Generation Antibody Therapies Market: Revenue Forecast, 2018-2028

5.3.4 United Kingdom Next-Generation Antibody Therapies Market: Revenue Forecast, 2018-2028

5.3.5 Italy Next-Generation Antibody Therapies Market: Revenue Forecast, 2018-2028

5.3.6 Spain Next-Generation Antibody Therapies Market: Revenue Forecast, 2018-2028

5.3.7 Russia Next-Generation Antibody Therapies Market: Revenue Forecast, 2018-2028

5.4 Asia-Pacific

5.4.1 Asia-Pacific Next-Generation Antibody Therapies Market by Country: Revenue Forecast, 2018-2028

5.4.2 Japan Next-Generation Antibody Therapies Market: Revenue Forecast, 2018-2028

5.4.3 China Next-Generation Antibody Therapies Market: Revenue Forecast, 2018-2028

5.4.4 Australia Next-Generation Antibody Therapies Market: Revenue Forecast, 2018-2028

5.4.5 South Korea Next-Generation Antibody Therapies Market: Revenue Forecast, 2018-2028

5.4.6 India Next-Generation Antibody Therapies Market, Revenue Forecast, 2018-2028

5.5 LAMEA

5.5.1 LAMEA Next-Generation Antibody Therapies Market by Country: Revenue Forecast, 2018-2028

5.5.2 Brazil Next-Generation Antibody Therapies Market: Revenue Forecast, 2018-2028

5.5.3 Saudi Arabia Next-Generation Antibody Therapies Market: Revenue Forecast, 2018-2028

5.5.4 Republic of South Africa Next-Generation Antibody Therapies Market, Revenue Forecast, 2018-2028

6. Antibody-Drug Conjugates: Market Forecast and Pipeline 2017-2028

6.1 Market Overview

6.2 Leading ADCs in 2017

6.3 Antibody-Drug Conjugates: Market Forecast 2017-2028

6.4 Adcetris

6.4.1 Adcetris: Sales 2013-2017

6.4.2 Adcetris Results in AETHERA Trial and Approval for in HL following Stem Cell Transplantation

6.4.3 Expanding Adcetris Indications for Future Revenue Growth

6.4.4 Adcetris Sales Forecast 2018-2028

6.5 Kadcyla

6.5.1 Mixed Results from Different Clinical Trials

6.5.2 NICE Rejects Kadcyla on Cost Grounds, but it Just Manages to Hold on in the Cancer Drugs Fund List

6.5.3 Kadcyla Sales Forecast 2018-2028

6.6 Mylotarg

6.6.1 Mylotarg Sales Forecast 2018-2028

6.7 Antibody-Drug Conjugate Platforms

6.7.1 Radioconjugation

6.7.2 Seattle Genetics’ Platform

6.7.3 ImmunoGen: TAP Technology

6.7.4 Immunomedics

6.7.5 Preclinical Platforms for ADC Development

6.8 ADCs Have Attracted High-Value Deals and Will Continue to do so

6.9 Antibody-Drug Conjugates: Pipeline Analysis 2017-2028

6.9.1 The Longest Pipeline in the Next-Generation Antibodies Market

6.9.2 Cancer Is the Only Target for Current Clinical-Stage ADCs

6.9.3 Seattle Genetics’ Phase 1 and Phase 2 ADCs

6.9.3.1 SGN-LIV1A (anti-LIV-1) for Relapsed Breast Cancer

6.10 Antibody-Drug Conjugates: Phase 3 Pipeline

6.10.1 CMC544 (inotuzumab ozogamicin, Pfizer)

6.10.1.1 Granted Breakthrough Therapy Designation

6.10.2 Roche Attempting to Expand Kadcyla Indications and also Possesses some Unique ADCs in the Pipeline

6.10.2.1 RG7596 (polatuzumab vedotin) for NHL and DLBCL

6.11 Antibody-Drug Conjugates: Phase 2 Pipeline

6.11.1 ABT-414 (anti-EGFR, AbbVie/Seattle Genetics)

6.11.2 BT-062 (indatuximab ravtansine; anti-CD138, Biotest)

6.11.3 Immunomedics’ IMMU-130 (labetuzumab-SN-38; anti-CEA/CD66e) and IMMU-132 (anti-TROP-2)

6.11.4 PSMA ADC (anti-PSMA, Progenics Pharmaceuticals/ Seattle Genetics)

6.12 Antibody-Drug Conjugates: Phase 1 Pipeline

6.13 Antibody-Drug Conjugates: Preclinical Pipeline

6.14 Future Developments in ADC Technology

6.14.1 Site-Specific Linkage for Improved Safety Profiles

7. Engineered Antibodies: Market Forecast 2017-2028

7.1 Market Overview

7.2 Leading Engineered Antibodies in 2017

7.3 Engineered Antibodies: Market Forecast 2017-2028

7.4 Gazyva/Gazyvaro

7.4.1 Gazyva/Gazyvaro Sales Forecast, 2018-2028

7.5 Poteligeo

7.5.1 Poteligeo Sales Forecast, 2018-2028

7.6 Engineered Antibodies Platforms

7.6.1 Roche Glycart: GlucoMAb

7.6.2 Kyowa Hakko Kirin: Potelligent

7.6.3 Glycotope: GlycoExpress

7.6.4 MacroGenics

7.6.5 Xencor: XmAb

7.7 Engineered Antibodies: Phase 3 Pipeline

7.7.1 Ublituximab (anti-CD20, TG Therapeutics)

7.7.2 MEDI-551 (anti-CD19, AstraZeneca)

7.7.3 MOR-208 (XmAb5574) (anti-CD19, MorphoSys/Xencor)

7.8 Engineered Antibodies: Phase 2 Pipeline

7.8.1 Glycotope’s CetuGEX (anti-EGFR), PankoMab-GEX (anti-TA-MUC1) and TrasGEX (anti-HER2)

7.8.2 Margetuximab (anti-HER2, MacroGenics)

7.8.3 Teplizumab (anti-CD3, MacroGenics)

7.8.4 XmAb5871 (anti-CD19, Xencor)

7.9 Engineered Antibodies: Phase 1 Pipeline

8. Bispecific Antibodies: Market Forecast 2017-2028

8.1 Market Overview

8.2 Bispecific Antibodies: Market Forecast 2017-2028

8.3 Blincyto

8.3.1 Blincyto Sales Forecast, 2018-2028

8.4 Bispecific Antibodies Platforms

8.4.1 BiTE Platform

8.4.2 MacroGenics’ DART Platform

8.4.3 TriomAbs (TRION Pharma)

8.4.4 Other Bispecific Antibody Platforms

8.4.4.1 DuoBodies (Genmab)

8.4.4.2 ImmTAC (Immunocore)

8.5 Bispecific Antibodies: Pipeline Analysis 2017-2028

8.6 Bispecific Antibodies: Phase 2 and Phase 3 Pipeline

8.6.1 ABT-981 (anti-IL-1α and IL-1β, AbbVie)

8.6.2 AFM13 (anti-CD30 and CD16A, Affimed Therapeutics)

8.6.3 MM-141 (anti-IGF-1R and ErbB3, Merrimack Pharmaceuticals)

8.6.4 SAR156597 (anti-IL-4 and IL-13, Sanofi)

8.7 Bispecific Antibodies: Phase 1, Phase 1/2 and Preclinical Pipeline

9. Antibody Fragments and Antibody-Like Proteins (ALPs): Market Forecast 2017-2028

9.1 Market Overview

9.2 Antibody Fragments and Antibody-Like Proteins (ALPs): Market Forecast 2017-2028

9.3 Kalbitor

9.3.1 Kalbitor Sales Forecast, 2018-2028

9.4 Antibody Fragments and ALPs Platforms

9.4.1 Single-chain Variable Fragment Platforms

9.4.1.1 ESBATech and Delenex Therapeutics

9.4.1.2 Nanobodies: The Smallest Antibody Fragment

9.4.1.3 Ablynx’s Nanobody Platform

9.4.1.4 Domain Antibodies: GSK and Crescendo Biologics

9.4.2 Non-Antibody Protein Scaffolds: Antibody-Like Proteins

9.4.2.1 DARPins: One-Tenth the Size of Antibodies

9.4.2.2 Anticalins (Pieris)

9.4.2.3 Affibodies (Affibody)

9.4.2.4 Fynomers (Covagen/Johnson & Johnson)

9.4.2.5 Affilins (Scil Proteins)

9.4.2.6 Adnectins (Bristol-Myers Squibb)

9.4.2.7 AdAlta: i-bodies

9.5 Antibody Fragments and ALPs: Pipeline Analysis 2017-2028

9.5.1 Ablynx Leads the Pipeline with Eight Clinical Projects

9.6 Antibody Fragments and ALPs: Phase 3 Pipeline

9.6.1 Caplacizumab (anti-vWF, Ablynx)

9.6.2 Abicipar (anti-VEGF, Allergan/Molecular Partners)

9.7 ESBA1008 (anti-VEGF, Novartis)

9.8 Antibody Fragments and ALPs: Phase 2 Pipeline

9.8.1 ALX-0061 (anti-IL-6R, Ablynx/AbbVie)

9.8.2 Ozoralizumab (anti-TNFα, Ablynx )

9.8.3 DLX105 (anti-TNF-α, Delenex Therapeutics)

9.8.4 ALX-0171 (anti-respiratory syncytial virus)

9.8.5 PRS-080 (Pieris Pharmaceuticals GmbH)

9.9 Antibody Fragments and ALPs: Phase 1 Pipeline

9.9.1 ALX-0761/M1095 (anti-IL-17A and IL-17F, Ablynx/Merck Serono)

9.9.2 ALX-0141 (anti-RANKL, Ablynx/Eddingpharm)

9.10 Other Phase 1 Candidates, and the Preclinical Pipeline

10. Biosimilar Antibodies: Market Forecast 2017-2028

10.1 Market Overview

10.2 Leading Biosimilar Antibodies in 2017

10.3 Biosimilar Antibodies: Market Forecast 2017-2028

10.4 Infliximab Biosimilar Sales Forecast, 2018-2028

10.5 Adalimumab Biosimilar Sales Forecast, 2018-2028

10.6 Rituximab Biosimilar Sales Forecast, 2018-2028

10.7 Trastuzumab Biosimilar Sales Forecast, 2018-2028

10.8 The Biosimilar Antibodies Market: Drivers and Restraints 2017-2028

10.8.1 New Launches of Biosimilar mAbs in Developed and Emerging Markets

10.8.2 Rising Incidence of Cancer Will Drive Demand

10.8.3 Novel mAb Developers Choosing to Develop Biobetters and Next-Generation Therapies in Face of Biosimilar Competition

10.8.4 Will Biosimilars Challenge Next-Generation Antibodies in this Decade?

11. Leading Companies in Next-Generation Antibody Therapies Market

11.1 Seattle Genetics Inc.

11.1.1 Company Overview

11.1.2 Operating Segments

11.1.3 Financial Highlights

11.1.4 Product Pipeline

11.1.5 Recent Strategic Developments

11.2 F. Hoffmann-La Roche Ltd.

11.2.1 Company Overview

11.2.2 Operating Segments

11.2.3 Financial Highlights

11.2.4 Product Pipeline

11.2.5 Recent Strategic Developments

11.3 Pfizer, Inc.

11.3.1 Company Overview

11.3.2 Operating Segments

11.3.3 Financial Highlights

11.3.4 Recent Strategic Developments

11.4 Kirin Holdings (Kyowa Hakko Kirin Co., Ltd.)

11.4.1 Company Overview

11.4.2 Operating Segments

11.4.3 Financial Highlights

11.4.4 Recent Strategic Developments

11.5 Sanofi S.A.

11.5.1 Company Overview

11.5.2 Operating Segments

11.5.3 Financial Highlights

11.5.4 Recent Strategic Developments

11.6 Merck KGaA (Merck Sereno)

11.6.1 Company Overview

11.6.2 Operating Segments

11.6.3 Financial Highlights

11.6.4 Recent Strategic Developments

11.7 Amgen Inc.

11.7.1 Company Overview

11.7.2 Operating Segments

11.7.3 Financial Highlights

11.7.4 Recent Strategic Developments

11.8 Novartis AG

11.8.1 Company Overview

11.8.2 Operating Segments

11.8.3 Financial Highlights

11.8.4 Recent Strategic Developments

11.9 GlaxoSmithKline plc

11.9.1 Company Overview

11.9.2 Operating Segments

11.9.3 Financial Highlights

11.10 Shire plc

11.10.1 Company Overview

11.10.2 Operating Segments

11.10.3 Financial Highlights



12. Qualitative Analysis of the Next-Generation Antibody Therapies Market 2017-2028

12.1 SWOT Analysis of the Next-Generation Antibody Therapies Market

12.1.1 Strengths: The Path Towards Market Acceptance

12.1.2 Weaknesses – Multiple Companies Targeting Similar Indications

12.1.2.1 Challenges Exist with Current Monoclonal Antibody Therapies

12.1.3 Opportunities: Novel Platforms

12.1.3.1 Big Pharmas are Investing Heavily in Next-Generation Pipelines

12.1.4 Threats: Entry of Biosimilars

12.1.4.1 Will Biosimilars Growth Slow Down in the Next-Generation Antibody Market?

12.2 Market Dynamics

12.2.1 Drivers

12.2.1.1 Rise in prevalence of cancer diseases

12.2.1.2 Increase in medical insurance coverage

12.2.1.3 Strong pipeline of drugs

12.2.2 Restraints

12.2.2.1 Risk of allergic reaction and limitations

12.2.2.2 Lengthy & stringent government regulations

12.2.3 Opportunities

12.2.3.1 Increasing R&D in cancer therapy

12.2.3.2 Increase in purchasing power of emerging economies

12.3 PEST Analysis of the Next-Generation Antibody Therapies Market

12.3.1 Political and Regulatory Issues

12.3.1.1 Regulatory Challenges for Biosimilar Antibodies

12.3.2 Economic Pressures

12.3.2.1 Next-Generation Antibodies Are High-Cost

12.3.2.2 Outsourced Manufacturing: CMOs Are Expanding Capabilities

12.3.2.3 Next-Generation Launches for Product Lifecycle Management

12.3.3 Social Factors

12.3.3.1 Cancer Incidence Is Rising Rapidly

12.3.3.2 Next-Generation Antibodies for Personalised Medicine

12.3.4 Technological Developments

12.3.4.1 There Are Many Competing Platforms

12.3.4.2 Manufacturing Challenges Exist for Most Sectors

12.3.4.3 New Analytical Tools for Target Identification and Protein Characterisation

12.4 Key Targets for Next-Generation Antibody Development 2017-2028

12.4.1 Oncology Is the Lead Indication in All Sectors

12.4.1.1 HER2 and HER3 for Breast Cancer

12.4.1.2 CD19 and CD20 for Lymphoma and Leukaemia

13. Conclusions

13.1 High Growth Potential in the Next-Generation Antibody Therapies Market in 20167-2028

13.2 Current Status of the Market and Leading Segments

13.3 Leading Next-Generation Antibody Therapies Profiled in this Report

13.4 Leading Regional Markets

13.5 Development of the Market to 2028

13.6 Technology Platforms Will Continue to Attract Big Pharma Interest

13.7 Most Developers Continue to Target Cancer

13.8 Strategies for Growth in 2017-2028

Appendices

Associated Visiongain Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain report evaluation form

List of Tables

Table 2.1 Monoclonal Antibody Types and Sources

Table 2.2 The Different Phases of Clinical Trials and What They Assess

Table 3.1 Global Next-Generation Antibody Therapies Market by Product: Revenue ($m) and Market Share (%), 2017

Table 3.2 Global Next-Generation Antibody Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028

Table 3.3 Global Next-Generation Antibody Therapies Market by Product: Revenue ($m) and Market Share (%), 2017 & 2028

Table 4.1 Global Next-Generation Antibody Therapies Market by Product Type: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 4.2 Global Antibody-Drug Conjugates Submarket: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 4.3: Global Engineered Antibodies Submarket: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 4.4 Global Bispecific Antibodies Submarket: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 4.5 Global Antibody Fragments and ALPs Submarket: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 4.6 Global Biosimilar Antibody Submarket: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 4.7 Global Next-Generation Antibody Therapies Market by Product Type: Revenue ($m), Revenue Share (%), 2017, 2023, 2028

Table 5.1 Global Next-Generation Antibody Therapies Market by Region: Revenue ($m), Revenue Share (%), 2017, 2023, 2028

Table 5.2 Global Next-Generation Antibody Therapies by Leading National Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.3 North America Next-Generation Antibody Therapies Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.4 US Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.5 Canada Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.6 Mexico Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.7 Europe Next-Generation Antibody Therapies Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.8 Germany Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.9 France Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.10 United Kingdom Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.11 Italy Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.12 Spain Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.13 Russia Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.14 Asia-Pacific Next-Generation Antibody Therapies Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.15 Japan Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.16 China Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.17 Australia Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.18 South Korea Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.19 India Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.20 LAMEA Next-Generation Antibody Therapies Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.21 Brazil Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.22 Saudi Arabia Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 5.23 Republic of South Africa Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 6.1 Antibody-Drug Conjugates Market by Type: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 6.2 Adcetris: Market Revenue ($m) 2013-2017

Table 6.3 Adcetris Market Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 6.4 Kadcyla: Market Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 6.5 Mylotarg Market Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 6.6 Seattle Genetics ADC Collaborator Pipeline

Table 6.7 Selected Preclinical ADC Development Platforms

Table 6.8 ADC Pipeline by Major Indications, 2017

Table 6.9 ADC Phase 3 Pipeline by Indication, 2018

Table 6.10 Selected Ongoing Clinical Trials for CMC544 (inotuzumab ozogamicin), 2018

Table 6.11 Roche’s Antibody-Drug Conjugates Pipeline, 2018

Table 6.12 Selected Ongoing Clinical Trials for RG7596 (polatuzumab vedotin), 2018

Table 6.13 ADC Phase 2 Pipeline by Indication, 2018

Table 6.14 Selected Ongoing Clinical Trials for ABT-414, 2018

Table 6.15 ADC Phase 1 Pipeline by Indication, 2018

Table 6.16 ADC Preclinical Pipeline, 2018

Table 7.1 Engineered Antibodies Market by Type: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 7.2 Gazyva/Gazyvaro Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 7.3 Poteligeo Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 7.4 Engineered Antibodies Phase 3 Pipeline by Indication, 2018

Table 7.5 Selected Ongoing Clinical Trials for MEDI-551, 2018

Table 7.6 Engineered Antibodies Phase 2 Pipeline by Indication, 2018

Table 7.7 Selected Ongoing Clinical Trials for Margetuximab, 2018

Table 7.8 Engineered Antibodies Phase 1 Pipeline by Indication, 2018

Table 8.1 Bispecific Antibodies Market by Type: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 8.2 Blincyto: Market Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 8.3 Bispecific Antibodies Pipeline by Indication and Phase, 2017

Table 8.4 Bispecific Antibodies Pipeline by Indication and Phase, 2018

Table 8.5 Bispecific Antibodies: Phase 1/2 Pipeline, 2018

Table 8.6 Bispecific Antibodies: Phase 1 Pipeline, 2018

Table 8.7 Bispecific Antibodies: Preclinical Pipeline, 2018

Table 9.1 Antibody Fragments and Antibody-Like Proteins (ALPs) Market by Type: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 9.2: Kalbitor Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 9.3 Antibody Fragments and ALPs Pipeline, 2018

Table 10.1 Biosimilar Antibody Market by Type: Revenue ($m), AGR (%) and CAGR (%) 2017-2028

Table 10.2 Infliximab Biosimilar Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 10.3 Adalimumab Biosimilar Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 10.4 Rituximab Biosimilar Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 10.5 Trastuzumab Biosimilar Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028

Table 10.6 Patent Status of Five Leading mAbs

Table 11.1 Seattle Genetics Inc. Operating Segments

Table 11.2 Seattle Genetics Inc.: Revenue ($m), R&D ($m), 2015-2017

Table 11.3 Seattle Genetics Inc. Product Pipeline

Table 11.4 Seattle Genetics Inc. Recent Developments

Table 11.5 Roche Operating Segments

Table 11.6 Roche: Revenue ($m), R&D ($m), 2015-2017

Table 11.7 Roche Product Pipeline

Table 11.8 Roche Recent Developments

Table 11.9 Pfizer Operating Segments

Table 11.10 Pfizer: Revenue ($m), R&D ($m), 2015-2017

Table 11.11 Pfizer Recent Developments

Table 11.12 Kyowa Hakko Kirin Operating Segments

Table 11.13 Kyowa Hakko Kirin: Revenue ($m), R&D ($m), 2015-2017

Table 11.14 Kyowa Hakko Kirin Recent Developments

Table 11.15 Sanofi Operating Segments

Table 11.16 Sanofi: Revenue ($m), R&D ($m), 2015-2017

Table 11.17 Sanofi Recent Developments

Table 11.18 Merck Operating Segments

Table 11.19 Merck: Revenue ($m), R&D ($m), 2015-2017

Table 11.20 Merck Recent Developments

Table 11.21 Amgen Operating Segments

Table 11.22 Amgen: Revenue ($m), R&D ($m), 2015-2017

Table 11.23 Amgen Recent Developments

Table 11.24 Novartis Operating Segments

Table 11.25 Novartis: Revenue ($m), R&D ($m), 2015-2017

Table 11.26 Novartis Recent Developments

Table 11.27 GSK Operating Segments

Table 11.28 GSK: Revenue ($m), R&D ($m), 2015-2017

Table 11.29: Shire Operating Segments

Table 11.30: Shire: Revenue ($m), R&D ($m), 2015-2017

List of Figures

Figure 1.1 Global Next-Generation Antibody Therapies Market, Market Segmentation

Figure 3.1 Global Next-Generation Antibody Therapies by Product: Market Share (%), 2017

Figure 3.2 Global Next-Generation Antibody Therapies Market Forecast Revenue ($m) & AGR (%), 2017-2028

Figure 3.3 Global Next-Generation Antibody Therapies Market by Product: Revenue ($m), 2028

Figure 3.4 World Next-Generation Antibody Therapies Market: Drivers and Restraints, 2017-2028

Figure 3.5 Global Next-Generation Antibody Therapies Market by Product: Revenue ($m), 2017-2028

Figure 4.1 Global Antibody-Drug Conjugates Submarket: Revenue ($m), 2017-2028

Figure 4.2 Global Engineered Antibodies Submarket: Revenue ($m), 2017-2028

Figure 4.3 Global Bispecific Antibodies Submarket: Revenue ($m), 2017-2028

Figure 4.4 Global Antibody Fragments and ALPs Submarket: Revenue ($m), 2017-2028

Figure 4.5: Global Next-Generation Antibody Therapies Market, Biosimilar Antibody Revenue ($m), 2017-2028

Figure 5.1 Global Next-Generation Antibody Therapies Market by Region: Revenue ($m), 2017-2028

Figure 5.2 US Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028

Figure 5.3 Canada Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028

Figure 5.4 Mexico Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028

Figure 5.5 Germany Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028

Figure 5.6 France Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028

Figure 5.7 United Kingdom Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028

Figure 5.8 Italy Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028

Figure 5.9 Spain Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028

Figure 5.10 Russia Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028

Figure 5.11 Japan Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028

Figure 5.12 China Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028

Figure 5.13 Australia Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028

Figure 5.14 South Korea Next-Generation Antibody Therapies Market, Revenue ($m), 2017-2028

Figure 5.15 India Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028

Figure 5.16 Brazil Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028

Figure 5.17 Saudi Arabia Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028

Figure 5.18 Republic of South Africa Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028

Figure 6.1 Antibody-Drug Conjugates Market Forecast: Revenue ($m) & AGR (%), 2017-2028

Figure 7.1 Engineered Antibodies Market Forecast: Revenue ($m) & AGR (%), 2017-2028

Figure 8.1 Bispecific Antibodies Market Forecast: Revenue ($m) & AGR (%), 2017-2028

Figure 9.1 Antibody Fragments and Antibody-Like Proteins (ALPs) Market Forecast: Revenue ($m) & AGR (%), 2017-2028

Figure 10.1 Biosimilar Antibody Market Forecast: Revenue ($m) & AGR (%), 2017-2028

Figure 12.1 Next-Generation Antibody Therapies Market: Strengths and Weaknesses, 2017-2028

Figure 12.2 Next-Generation Antibody Therapies Market: Opportunities and Threats, 2017-2028